CoChat

Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease

Open access

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index; 19 of the 125 sources its claims cite were checked for support.

Abstract

Integrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the potential for a holistic endo-histo-omics approach by interlacing and harmonising endoscopy, histology, and omics data towards precision medicine. The emerging applications of artificial intelligence could pave the way for personalised medicine in IBD, offering patient stratification for the most beneficial therapy with minimal risk. Although artificial intelligence holds promise, challenges remain, including data quality, standardisation, reproducibility, scarcity of randomised controlled trials, clinical implementation, ethical concerns, legal liability, and regulatory issues. The development of standardised guidelines and interdisciplinary collaboration, including policy makers and regulatory agencies, is crucial for addressing these challenges and advancing artificial intelligence in IBD clinical practice and trials.

Overview

CoChat Summary

TL;DR

This review argues that AI can standardize and improve IBD endoscopy and histology assessment and, when fused with OMICs, enable an “Endo-Histo-OMICs” precision-medicine approach. It also emphasizes unresolved challenges in data quality, reproducibility, explainability, bias, privacy, and regulation.

Key findings

  • In IBD endoscopy, a meta-analysis of 12 studies found CNN-based deep learning for UC severity had pooled accuracy 91.5%, sensitivity 82.8%, and specificity 92.4%; UCEIS outperformed MES for sensitivity (94% vs 82%) and positive predictive value (94% vs 84%). AI-PICaSSO was associated with adverse outcomes (HR 4.05) similarly to human endoscopists (HR 4.59), and EndoBRAIN-UC predicted 12-month clinical relapse in 28.4% of the AI-active group vs 4.9% in the AI-healing group (p<0.001).
  • For advanced and capsule endoscopy, a CNN using VCE/PICaSSO detected endoscopic remission better than WLE/UCEIS (sensitivity 79% vs 72%; specificity 95% vs 87%; AUROC 0.94 vs 0.85). AI-assisted pan-enteric capsule endoscopy reduced images for review from 2,965,900 to 86,129 (97.1% reduction), with pooled median review time 3.2 min per patient and observer sensitivity/specificity of 96%/93% and 92%/90%.
  • In histology, a PHRI-based deep learning strategy analyzed 614 digitized biopsies from 302 UC patients and predicted histological remission with 80% accuracy in validation and 79% in testing. Other models predicted NHI score with k=0.91 and ⍴=0.89 and histological remission with accuracy 0.97; a CD model using 550 surgical slides predicted postoperative recurrence with AUROC 0.995; and AI-modelled GHAS/Geboes matched central reading with accuracies of 80–89% for GHAS in colon, 65–82% in ileum, and 65–85% for Geboes.
  • In the “Endo-Omics” exploratory study of 29 IBD patients, in-vivo pCLE features predicted response to infliximab/vedolizumab with 85% accuracy in UC and 80% in CD; ex-vivo fluorescent biologic binding predicted response with AUROC 83%, accuracy 77%, PPV 89%, and NPV 50%, and a differentially expressed gene panel showed AUROC >0.7 for anti-TNF response.

Methods

  • Narrative review; references were identified in December 2023 through PubMed searches using terms including “Inflammatory Bowel Disease,” “Ulcerative Colitis,” “Crohn’s Disease,” “Endoscopy,” “Advanced imaging,” “Endocytoscope,” “Confocal laser endomicroscopy,” “Histology,” “OMICs,” “RNA Transcriptomics,” “Microbiome,” “Precision Medicine,” “Machine Learning,” “Deep Learning,” and “Artificial Intelligence,” for all articles since database inception.
  • Additional articles were identified from reference lists of pivotal review articles, and the final reference list was generated based on originality and relevance to the broad scope of the review.
  • No primary patient data or new experimental analysis were generated; the paper synthesizes published studies and presents overview tables and conceptual figures.

Limitations

  • Stated by the paper: challenges include data quality, standardization, reproducibility, clinical implementation, ethical concerns, legal liability, and regulatory issues; meta-analyses showed moderate-to-high heterogeneity; AI data in CD histology remain limited; external validation in large, diverse cohorts is needed; human-centric and methodology-centric biases persist; and AI-specific regulatory frameworks are lacking.
  • Evident from the text: this is a narrative review rather than a systematic review, with a search limited to December 2023 PubMed plus selected reference lists and no formal risk-of-bias or quality appraisal; several cited studies are small or exploratory (e.g., 5 CD patients, 29 IBD patients), and some AI histology work reports incomplete diagnostic metrics (e.g., Peyrin-Biroulet and colleagues did not report specific diagnostic metrics).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(24)00053-0

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 5 Not valid · 82 Not checked · 23 Own results and interpretations

48 more claims · 1 with their cited sources checked

Create a free account to see all 119 claims and to verify the 106 references still open.

See all claims — free account
  • It may state two separate claims as one. 51
  • Probably not a substantial claim. 30

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 124 references

Research works printed but not linked: 1

  1. Sun Y, Guo C, Li Y. ReAct: Out-of-distribution detection with rectified activations. In: Ranzato M, Beygelzimer A, Dauphin Y, Liang PS, Wortman Vaughan J, eds. Advances in Neural Information Processing Systems, 34 (NeurIPS 2021), pp 1–13.

Cited by

See all 73

Metadata

Authors
Iacucci, M., Santacroce, G., Zammarchi, I., Maeda, Y., Del Amor, R., Meseguer, P., Kolawole, B. B., Chaudhari, U., Di Sabatino, A., Danese, S., Mori, Y., Grisan, E., Naranjo, V., & Ghosh, S.
Affiliations
  • University College Cork (IE)
  • Universitat Politècnica de València (ES)
  • London South Bank University (GB)
  • Vita-Salute San Raffaele University (IT)
  • University of Oslo (NO)
Corresponding author
Iacucci, Marietta
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2024-08
Volume
9
Issue
8
Pages
758-772
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W4396936366
Cited by
73
References
117
Citations by year
2026: 30 · 2025: 35 · 2024: 8
FWCI
4.96
Type
journal article
Language
en
Open access
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Open (London South Bank University) (acceptedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
Keywords
artificial intelligence, inflammatory bowel disease, endoscopy, histology, precision medicine, disease activity assessment, endoscopic scoring, outcome prediction, patient stratification, personalized medicine, data quality, reproducibility, clinical implementation, regulatory challenges
MeSH terms
Artificial Intelligence, Humans, Inflammatory Bowel Diseases, Endoscopy, Gastrointestinal, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease. https://app.cochat.ai/papers/10.1016/s2468-1253(24)00053-0
The paper
Iacucci, M., Santacroce, G., Zammarchi, I., Maeda, Y., Del Amor, R., Meseguer, P., Kolawole, B. B., Chaudhari, U., Di Sabatino, A., Danese, S., Mori, Y., Grisan, E., Naranjo, V., & Ghosh, S. (2024). Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(24)00053-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.